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abstRact
IntroductIon: The aim of this article was to evaluate the 
awareness and use of the smartphone application (app) 
“Pregnant with Diabetes” locally, nationally and interna­
tionally.
Methods: In 2013, a patient initiated collaboration with 
the staff at Centre for Pregnant Women with Diabetes, Rigs­
hospitalet, to develop the app “Pregnant with Diabetes”. 
The app communicates clinically important antenatal health 
information to women with diabetes, based on recommen­
dations from our centre. Women with pre­existing diabetes 
(Type 1 and Type 2 diabetes) completed an anonymous, 
structured questionnaire at their first antenatal visit in early 
pregnancy at our centre. National and international data on 
numbers of downloads were obtained from Google Play, 
from the App Store and from Google Analytics.
results: Among 139 pregnant women with diabetes (96 
with Type 1 diabetes and 43 with Type 2 diabetes), 99% had 
a smartphone and 75% had downloaded the app, whereof 
48% had obtained information from the app before their 
pregnancy. In July 2017, the app had been downloaded 
4,465 times in Denmark and 27,361 times in a total of 183 
countries. The topics most frequently visited were “diet and 
carbohydrates”, “blood glucose” and “possible complica­
tions”.
conclusIons: Easily accessible patient information made 
available via app technology reaches the patients and may 
contribute to improved pregnancy planning and outcome in 
women with pre­existing diabetes ­ locally, nationally and 
internationally.  
FundIng: The app was sponsored by Novo Nordisk, Bayer 
A/S, Diabetes Care, Abbott, MSD Denmark, A.D.I.P.S and 
Rigshospitalet. 
trIal regIstratIon: not relevant. 
In women with diabetes, optimal glycaemic control be­
fore and during pregnancy is important to prevent an 
adverse pregnancy outcome, including congenital mal­
formations and foetal overgrowth [1]. Patient education 
and involvement is crucial in order to improve diabetes 
self­management and glycaemic control prior to and 
during pregnancy [2]. A smartphone application (app) is 
an easily accessible tool that can communicate import­
ant health information. Several apps are already avail­
able for the non­pregnant population with diabetes,  
and they may have positive effects on glycaemic control 
[3, 4].
In 2013, a patient (HMJ) initiated collaboration with 
the staff at Centre for Pregnant Women with Diabetes, 
Rigshospitalet, to develop the smartphone app “Preg­
nant with Diabetes”.  The primary target group for the 
app is pregnant women with pre­existing diabetes, but 
the app also includes information for women with gesta­
tional diabetes specifically, as well as for women with  
diabetes who are planning pregnancy. The aim of the 
app is to communicate clinically important antenatal 
health information to women with diabetes, and that 
enhanced knowledge at the patient level will lead to im­
proved pregnancy outcomes. The app is an educational 
tool that includes evidence­based clinical recommenda­
tions from our centre [5]. The intention is to communi­
cate such information in an easily understandable lan­
guage tailored to the patients. Danish and English 
versions of the app have been available since 2014. In 
2015, a Swedish version was launched and a version tai­
lored for Australia was added in 2016 [6]. 
To our knowledge, the use of an informative app 
designed for pregnant women with diabetes has not 
previously been explored. The app technology easily 
crosses national borders, and the aim of the present 
study was to evaluate the awareness and use of the app 
locally, nationally and internationally. 
mEthOds
The app (table 1) includes the following 13 topics of im­
portance for motivating and executing self­care of dia­
betes treatment during pregnancy and in the pregnancy 
planning phase; “What is diabetes”, “Pregnancy plan­
ning”, “Possible complications”, “Blood glucose”, 
“Weight gain”, “Diet and carbohydrates”, “Physical ac­
tivity”, “The foetus”, ”Insulin dose”, “In need of assis­
tance”, “Scans”, “Delivery” and “After birth”. Every topic 
can be selected from a wheel of illustrative icons on the 
front page of the app (Figure 1). The app is available free 
of charge at Google Play and App Store.
In the period from May 2015 to February 2017, a 
total of 274 pregnant women with pre­existing diabetes 
(Type 1 and Type 2 diabetes) were referred to the 
Use of the smartphone application  
“Pregnant with diabetes”
Sidse Kjærhus Nørgaard1, 2, Vibeke Ladefoged Nichum1, Charlotte Barfred1, Hellen Marguerite Juul1, Anna Lilja Secher1, 2, Lene Ringholm3,  
Peter Damm1, 4, 5 & Elisabeth Reinhardt Mathiesen1, 2, 4
ORiginal 
aRticlE
1) Centre for Pregnant 
Women with Diabetes, 
Rigshospitalet 
2) Department of 
Endocrinology, 
Rigshospitalet 
3) Steno Diabetes 
Centre Copenhagen 
4) Clinical Institute of 
Medicine, Faculty of 
Health and Medical 
Sciences, University of 
Copenhagen 
5) Department of 
Obstetrics,  
Rigshospitalet, 
Denmark
  
Dan Med J 
2017;64(11):A5417
 2   da n i s h m E d i c a l J O U R n a l Dan Med J 64/11   November 2017
Centre for Pregnant Women with Diabetes, Rigshos­
pitalet, Copenhagen, Denmark. At their first antenatal 
visit, the women were given an anonymous, structured 
questionnaire regarding the use and knowledge of the 
app. Women with gestational diabetes were not includ­
ed.
The questionnaire was developed for the present 
study and included 13 questions in total. The ques­
tions covered awareness of and access to the app, use 
of the app before and during pregnancy, how the 
women preferred to receive antenatal health infor­
mation (Table 1) and topics most frequently visited 
(table 2). The women were also asked how many 
times they had used the app, and if the app made 
them feel more secure. Furthermore, they were asked 
about their diabetes type and glycated haemoglobin 
level (HbA1c) at their first antenatal visit (questions 
8­11). HbA1c reflects the average blood glucose levels 
over the past three months, and thus HbA1c at the 
first antenatal visit reflects blood glucose in the plan­
ning phase as well. Questions 12 and 13 were op­
tional and allowed the respondents to provide pro­
posals for improvement of and comments to the app 
and were not included in this paper. Questionnaires 
were obtained from 175 (64%) of the 274 women 
whereof 36 were excluded due to missing information 
on diabetes type (question 10), leaving available 
ques tionnaires from 139 (51%) women (96 with Type 
1 diabetes and 43 with Type 2 diabetes). National and 
international data on the use of the app were ob­
tained from Google Play, from the App Store and from 
Google Analytics in July 2017 [7]. Access to Google 
Play, the App Store and Google Analytics was adminis­
tered by the app administrator (HMJ). The total num­
ber of national and international downloads of the 
app was collected in Google Play and in the App 
Store. Google Analytics was initially implemented in 
the app in order to track data regarding the use of the 
app. The following data were collected in July 2017 
from Google Analytics: The countries with at least one 
download of the app, the frequency of visits to the 
different topics in the app in total, the average time 
used per access to the app (minutes) and if the app 
was used more than one time by the same user (re­
peated user).  
statistical analyses
The results are given as mean ± standard deviation or 
median (range) for continuous variables and as number 
(%) for categorical variables. Results are presented for 
all included women as well as for women with Type 1 or 
Type 2 diabetes separately. Unanswered questions that 
were considered relevant for the respondent were clas­
sified as missing data. Statistical analyses were per­
tablE 1
The use of the smartphone app ”Pregnant with Diabetes” in pregnant women with pre­existing 
 diabetes: questions 1­6a. The values are n (%).
no. Question
type 1 diabetes 
(n = 96)
type 2 diabetes 
(n = 43)
all women  
(n = 139)
1 Do you have a smartphone? 96 (100) 41 (95) 137 (99)
2 Are you aware of the app? 94 (98) 38 (88) 132 (95)
3 From where do you know about the app?b, c 
Your local diabetes centre 39 (41) 18 (47)   57 (43)
The Centre for Pregnant Women with 
Diabetes
27 (29) 13 (34)   40 (31)
The Internet 12 (13)   4 (11)   16 (12)
Facebook or friends   7 (7)   0 (0)     7 (5)
Other   9 (10)   3 (8)   12 (9)
4 Have you downloaded the app? 76 (79) 28 (65) 104 (75)
5 When was the 1st time you used the app?d 
Before pregnancy 38 (50) 12 (43)   50 (48)
6 How do you prefer to receive antenatal  
health informationb, e?  
Via an app 32 (39) 19 (50)   51 (43)
Via an app in combination with a home­
page and/or a paper sheet
29 (35) 12 (32)   41 (34)
Via a homepage and/or a paper sheet 21 (26)   7 (18)   28 (23)
a) Answers and data were available in 90­100% of the cases. 
b) > 1 answer allowed. 
c) % of those who know the app. 
d) % of those who have downloaded the app.
e) Type 1: n = 82, Type 2: n = 38.  
FigURE 1
Front page and the main menu of the smartphone app: “Pregnant with Diabetes”.
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formed using IBM SPSS Statistics 22 (SPSS, Chicago, IL, 
USA).
Trial registration: not relevant. 
REsUlts
The vast majority of pregnant women with pre­existing 
diabetes owned a smartphone (99%) and were aware of 
the app (95%), mainly from their local diabetes centres 
(43%) or from our centre (31%) (Table 1). At the first  
antenatal visit, 75% of the women had downloaded the 
app (Table 1) and used it up to ten times with a median 
of two times (question 8). Of those who had download­
ed the app, 48% had obtained information from the app 
before their pregnancy (Table 1). 
Data on HbA1c in early pregnancy was reported in 
87% of the questionnaires (question 11). HbA1c was 6.5 ± 
3.1% (48 ± 10.8 mmol/mol) by those who had used the 
app in the planning phase (question 5) of their preg­
nancy compared with 6.7 ± 3.4% (50 ± 13.3 mmol/mol) 
by those first obtaining knowledge from the app in early 
pregnancy (p = 0.47) (question 5).
The topics most frequently visited (Table 2) were 
“Blood glucose”, “The foetus” and “Insulin dose” among 
the total cohort of women with pre­existing diabetes 
and among women with Type 1 diabetes. For women 
with Type 2 diabetes, the most frequently visited topics 
were “Diet and carbohydrates”, “Blood glucose” and 
“What is diabetes”. 
The majority of the women (70%) reported that the 
app made them feel more secure about their diabetes 
and pregnancy (question 9). Most women (77%) pre­
ferred to receive antenatal health information via an 
app, either unaccompanied or in combination with a pa­
per sheet and/or a homepage (Table 1). Only 23% pre­
ferred a paper sheet and/or homepage.
In July 2017, the app had been downloaded 4,465 
times in Denmark and 27,361 times in 183 different 
countries worldwide, mainly in developed countries but 
also in developing countries (Figure 2). A total of 55% of 
the knowledge seekers worldwide were repeated users 
with an average use of three minutes per access to the 
app. The topics most frequently visited worldwide were 
“Diet and carbohydrates”, “Blood glucose” and “Possible 
complications”. The three countries with the highest 
numbers of users were The United States of America, 
Denmark and Australia for iOS (Apple) smartphones and 
The United States of America, India and Denmark for 
Android smartphone. 
discUssiOn
In a local cohort of pregnant women with pre­existing 
diabetes we observed a frequent use of the app “Preg­
nant with Diabetes”, with half of the users obtaining in­
formation from the app already when planning their 
pregnancy. The majority of the women preferred to re­
ceive the patient­tailored antenatal healthcare informa­
tion via app technology rather than by paper sheets.  
Internationally, the app was downloaded by almost 
22,000 individuals covering the majority of countries 
worldwide. The educational information in this app 
probably does reach the local, national and international 
community of pregnant women with diabetes much  
easier than a book or leaflet. Additionally, an app may 
updated more easily, and the information specifying the 
topics most frequently visited in the app affords the  
authors with an opportunity to focus and update specific 
information. 
The information included in the app was evi­
dence­based at the highest possible level as judged by 
two experienced clinical scientists in the area of diabe­
tes and pregnancy with both obstetric and endocrine ex­
perience [5]. During development of the app, it was de­
cided to include educational information without other 
facilities, such as a feedback system between patients 
and their caregivers. It is, however, possible to combine 
the use of the app “Pregnant with Diabetes” with other 
apps, for example an app for carbohydrate counting and 
also apps for calculation of meal­time insulin dose based 
on the individual carbohydrate­to­insulin ratio.
Today, smartphones are widely used among women 
of childbearing age, and nearly all of the pregnant  
women in our population have a smartphone [8]. The 
app technology is also widely used in other countries 
such as the United States of America and India, where 
rates of smartphone ownership are similar across ethnic 
tablE 2
The use of the different topics. Question 7:” Which topics have you used in the app?”, included in the 
smartphone app ”Pregnant with Diabetes” in pregnant women with pre­existing diabetesa. The values 
are n (%)b.
topic title
type 1 diabetes  
(n = 70)
type 2 diabetes  
(n = 23)
all women  
(n = 93)
”What is diabetes?” 14 (20) 13 (56) 27 (29)
”Planning” 33 (47)   8 (35) 41 (44)
”Possible complications” 43 (61) 11 (48) 54 (58)
“Blood glucose” 50 (71) 17 (74) 67 (72)
“Weight gain” 41 (44) 12 (52) 53 (57)
”Diet and carbohydrates” 40 (57) 18 (78) 58 (62)
“Physical activity” 28 (40) 10 (43) 38 (41)
”The foetus” 49 (70) 10 (43) 59 (63)
”Insulin dose” 48 (69) 11 (48) 59 (63)
”In need of assistance” 19 (27)   9 (39) 28 (30)
”Scans” 41 (59)   9 (39) 50 (54)
”Delivery” 33 (47)   7 (30) 40 (43)
”After birth” 23 (33)   6 (26) 29 (31)
a) > 1 answer allowed. 
b) % of those w  ho have downloaded and used the app.
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groups and communities with different levels of income 
and access to healthcare [8, 9].  
Several apps for patients with diabetes are available 
[10], but to our knowledge this study is the first to ex­
plore the awareness and use of an informative app, de­
signed for pregnant women with diabetes and those 
planning their pregnancy. This study includes single cen­
tre questionnaire­based data in pregnant women with 
diabetes. To improve the applicability (external validity), 
data on national and international downloads of the app 
were also included. Women followed at our centre, 
where the app was developed, may be more aware of 
the app than women visiting other centres, and our cen­
tre may therefore have a higher number of users of the 
app than other diabetes centres, which may bias our 
findings. Nevertheless, our results show that the major­
ity of the women knew the app from their local diabetes 
centre. It is a limitation that only 51% of the women re­
ferred to our centre in the study period completed the 
questionnaire, which may also bias our findings. How­
ever, the missing dataset was related mainly to days 
when the nurses were busy and had to prioritise their 
clinical work over the collection of research questions, 
suggesting that the dataset may be considered to be 
representative of the whole population.  
The large number of downloads may represent the 
use of the app by both women with diabetes and by 
healthcare professionals or relatives. The use of the app 
by healthcare professionals, in Denmark and interna­
tionally, may be important to upgrade their own know­
ledge about diabetes and pregnancy, but also to guide 
the patients in selecting appropriate apps with evi­
dence­based knowledge within this field [11, 12]. 
The information in the app reached half of the 
women in the pregnancy planning phase and the major­
ity were repeated users, which documents a clinically 
relevant awareness and use of the app. The app contri­
butes knowledge about the importance of good glyc­
aemic control and folic acid intake prior to pregnancy, 
which may lead to a reduced prevalence of malforma­
tions in women with pre­existing diabetes. Data from 
this study point in the direction of a lower HbA1c in early 
pregnancy in those who used the app in the pregnancy 
planning phase. Knowledge from the app may have a 
positive influence on the obtained glycaemic control in 
early pregnancy, but the women seeking the informa­
tion may also have a better compliance in general and 
be able to obtain better glycaemic control than the less 
privileged part of our patient population. Future studies 
including a qualitative assessment of the women’s ex­
periences from their use of the app are needed to fur­
ther elucidate whether the app contributes significantly 
to an improved glycaemic control and pregnancy out­
come in women with pre­existing diabetes. 
The present patient population comes from a soci­
ety with a high level of daily internet use and computer 
skills, and the women had generally obtained good glyc­
aemic control. HbA1c was self­reported based on meas­
urement performed the same day, and at a similar level 
as previously reported in a similar patient population 
from our centre [13]. The results are probably applicable 
to other societies, including Third World countries. App 
technology may have the potential to provide informa­
tion and reach otherwise inaccessible women in rural  
areas and third world countries [8]. Worldwide, use of 
smartphones is increasing, and on average half of the 
world’s population now use a smartphone [14]; these 
figures are probably even higher among young women 
of childbearing age. 
cOnclUsiOns
The app “Pregnant with Diabetes” is widely known 
and used, and antenatal health information in an app  
is preferred to other media by pregnant women with 
pre­existing diabetes. Information via app technology 
has the potential to reach the women immediately,  
even in rural areas and developing countries. Improved 
knowledge obtained from the app may contribute to  
improved pregnancy planning and outcome ­ locally,  
nationally and internationally. 
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FigURE 2
Worldwide downloads of the app “Pregnant with Diabetes (August 2017)
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